# A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

> **NCT01499446** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 669 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GW685698X (fluticasone furoate) 100mcg Morning
- **DRUG:** GW685698X (fluticasone furoate) 100mcg Evening
- **DRUG:** GW685698X (fluticasone furoate) 250mcg Evening
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01499446
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 669 (ACTUAL)
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01499446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01499446, "A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01499446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*